AIM ImmunoTechのAmpligen薬はImfinziと併用され,前期的な臓がん試験で好結果と耐容性を示しています. AIM ImmunoTech's Ampligen drug in combo with Imfinzi shows promise in late-stage pancreatic cancer trial with positive results and tolerability.

AIM ImmunoTechは,AstraZenecaのImfinziと併用した薬 Ampligenの第1b/2期試験の予備的な有望な結果を発表しました. AIM ImmunoTech has announced promising preliminary results from a Phase 1b/2 trial of its drug Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer. 治療はよく耐えており,重度の副作用は認められませんでした. The therapy was well-tolerated, with no severe side effects noted. 注目すべきは,初期グループ内の3人の患者のうち2人が6ヶ月後の安定性評価に達したことです. Notably, two of three patients in the initial group reached the six-month stability assessment. AIM ImmunoTechは癌,免疫障害,ウイルス性疾患の治療に特化しています. AIM ImmunoTech specializes in treatments for cancer, immune disorders, and viral diseases.